Dr. Pusztai on Evolution of Treatment for HER2+ Breast Cancer
In Partnership With:
Lajos Pustzai, MD, DPhil, professor of Medicine (Medical Oncology), chief of Breast Medical Oncology, co-director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale Cancer Center, discusses how treatment for patients with HER2-positive breast cancer has evolved.
Lajos Pustzai, MD, DPhil, professor of Medicine (Medical Oncology), chief of Breast Medical Oncology, co-director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale Cancer Center, discusses how treatment for patients with HER2-positive breast cancer has evolved over time.
One of the first successful examples of treatment for this patient population is trastuzumab (Herceptin), Pusztai explains.
In the wake of this agent's development, two more promising therapies have been added to the field, which are pertuzumab (Perjeta) and ado-trastuzumab emtansine (T-DM1). These drugs have demonstrated efficacy in both the early-stage and late-stage settings, he adds.
